Daiichi Sankyo Co Ltd R&D Day Transcript
[Interpreted] I am Manabe. Thank you for joining us today at Daiichi Sankyo's R&D Day.
This fiscal year, we have updated our R&D strategy from 3 and Alpha to 5DXd ADCs and Next Wave in line with the strong progress of our pipeline. In particular, the expansion of the ENHERTU indications has progressed very well, and we have also received clinically meaningful clinical trial data for the other 4, 5 DXd ADCs assets, making it a very productive year.
We have been accumulating positive data for ENHERTU and Dato-DXd with a view to expanding other indications, or obtaining regulatory approval and under the strong collaboration with AstraZeneca that we have established to date. We will continue to pursue the maximization of product values. For HER3-DXd DS-7300 and DS-6000. The accumulation of favorable data has further enhanced the potential and moved them to the stage. We plan to maximize the product value. In addition to these changes in our internal environment, externally, competition of ADC
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
